Ursula Matulonis on Muck Rack

Ursula Matulonis

Boston
As seen in: Nature, Genome Medicine, Medscape, The Lancet, Healio, HemOnc Today, Cold Spring Harbor Perspectives in Medicine (Online), ONCOLOGY journal, CURE Magazine, The ASCO Post and
Chief, Division of Gynecologic Oncology at the Dana-Farber Cancer Institute. Tweets are my own & not medical advice #gyncsm
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ursula

Contact Ursula, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer

|
By Han Dong, Arindam Ray, Jinhua Wang, Isabella N. Grabski, Lulu Wang, Kun Huang, Ye Tian, Maxime Meylan, Graham Barlow Verified, Chenyang Yu, Mahesh Raundhal, Sung-Hee Yoon, Liya Ding, Jean J. Zhao, Ursula Matulonis, Marc Foretz, Kai W. Wucherpfennig, Rafael Irizarry, Marc N. Wein, Laurie H. Glimcher, Lara K. Rotter, Heemaja Mewada, Shreya Nakhawa
| Nature Verified
Abstract Patients with metastatic high-grade serous ovarian carcinoma are often unresponsive to immunotherapies; here we identify salt-inducible kinases (SIKs) as key drivers of immunosuppression. Human T cells in the presence of patient ascites express high levels of SIK and the upstream kinase LKB1, whereas SIK inhibition reprograms human T cells and strongly activates antitumor responses.
Open in Who Shared Issue with article?

Endometrial Cancer: SWI/SNF Complexes, GLP-1 Receptor Agonists, and the Future of Research and Treatment

|
By Ursula Matulonis, Jessica St. Laurent
| Medscape Verified
Episode Transcript This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Ursula A. Matulonis, MD: Hello. I'm Dr Ursula Matulonis. Welcome to season 3 of the Medscape InDiscussion podcast series on endometrial cancer.
Open in Who Shared Issue with article?

Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer

|
By Xin Cheng, Yadong Zhang, Guruprasad Ananda, Tao Jiang, Jing Ni, Shaozhen Xie, Hao Gu, Elena Ivanova, Marisa R Nucci, Zhe Wang, Kaifu Chen, Bose Kochupurakkal, Gordon Freeman, Geoffrey I. Shapiro, Joyce Liu, Panagiotis A. Konstantinopoulos, Ursula Matulonis, Jean J. Zhao, Changli Qian, Erica Holdridge, Renlei Ji
| Nature Verified
Abstract Serous endometrial cancer (SEC) is an aggressive subtype of endometrial cancer (EC) with poor prognosis and limited treatment options. Here, we develop a clinically relevant, immunocompetent serous-like mouse model incorporating oncogenic PIK3CA mutation, Trp53 loss, and MYC overexpression. Using this model together with human EC cell lines, patient-derived organoids (PDOs), xenografts, and patient datasets, we investigate mechanisms underlying resistance to PI3Kα-targeted therapy.
Open in Who Shared Issue with article?
See all 61 licensed articles (101 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified